Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Boston Medical Group vs SynergenX Health

Boston Medical Group
Graded #279

Higher grade

vs+3.5
SynergenX Health
Graded #374

Lower grade

The verdict

Boston Medical Group takes it — 61.9/100 to 58.4/100.

Boston Medical Group grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Boston Medical Group is an established medical group running a 12-week compounded GLP-1 weight-loss programme.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueBoston Medical Group +8
54
46
Dose & formulationEven
52
52
Clinical oversightBoston Medical Group +23
89
66
Labs & monitoringSynergenX Health +33
53
86
FulfillmentBoston Medical Group +10
65
55
Contract termsBoston Medical Group +8
55
47
Boston Medical Group · left barSynergenX Health · right bar

The numbers

MetricBoston Medical GroupSynergenX Health
WeighScore61.9/10058.4/100
GradeCC
Scorecard rank#279#374
Semaglutide$199/mo (starting strength, rising with dose, compounded)$150/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosedNot disclosed
Coverage7 states10 states
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Boston Medical Group

Graded #279 · C

Strengths

  • An established medical group with a defined 12-week programme rather than an open-ended subscription
  • The price range and the 12-week total are both published, once you reach the costs page
  • Semaglutide is prescribed and dispensed under a compounded pathway with clinician oversight

Where it loses points

  • The published rate is a range by dose strength, $199 to $299, so the figure quoted is the floor rather than what a titrated patient pays
  • The 12-week programme totals $699 including a telemedicine platform fee that is never itemised — about $233/mo all-in, not $199
  • The weight-loss landing page carries no price at all; the numbers are two pages deeper, in the FAQ and the costs page
  • Semaglutide and tirzepatide are not priced separately — one range covers the whole programme
  • Compounded semaglutide and tirzepatide are not FDA-approved finished products
SynergenX Health

Graded #374 · C

Strengths

  • Compounded semaglutide from $150/mo including medication and refrigerated home shipping — no hidden fees stated on site
  • Backed by 64-clinic chain operating across 10 states with medical providers for in-person or telehealth care
  • Telehealth consultations from home; $100 initial visit, $40 follow-up every 1–3 months
  • Nutrition counseling and lifestyle planning included as part of personalized treatment program
  • Free weight-loss consultation option available before committing to paid evaluation

Where it loses points

  • Telehealth GLP-1 program currently Texas-only; rolling out more states but no timeline published
  • Tirzepatide not confirmed for online program; only compounded semaglutide explicitly listed
  • Labs not included or mentioned; no baseline bloodwork protocol disclosed on website
  • Dose-escalation pricing not published; $150/mo is entry dose only, higher doses may cost more
  • No LegitScript, named medical director, or publicly disclosed compounding pharmacy partner found

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard